[HTML][HTML] Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric …
LM Hoffman, L Gore - Frontiers in oncology, 2014 - frontiersin.org
… Lia Gore is the principal investigator of a clinical trial using blinatumomab in pediatric
patients. She is a member of Amgen’s Scientific Advisory Board for blinatumomab. …
patients. She is a member of Amgen’s Scientific Advisory Board for blinatumomab. …
[HTML][HTML] Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials
DA Pollyea, JA Gutman, L Gore, CA Smith… - …, 2014 - ncbi.nlm.nih.gov
Despite an increasingly rich understanding of its pathogenesis, acute myeloid leukemia
remains a disease with poor outcomes, overwhelmingly due to disease relapse. In recent years, …
remains a disease with poor outcomes, overwhelmingly due to disease relapse. In recent years, …
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American …
…, M Albitar, M de Lima, L Gore… - American journal of …, 2019 - Wiley Online Library
Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor
of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of …
of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of …
[HTML][HTML] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY …
…, L Gore, L Chow, S Leong, L Maloney… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
… Hanson, Lia Gore, Laura Chow, Stephen Leong, Lara Maloney, Gilad Gordon, Heidi
Simmons, Allison Marlow, Kevin Litwiler, Suzy Brown, Gregory Poch, Katie Kane, Jerry Haney …
Simmons, Allison Marlow, Kevin Litwiler, Suzy Brown, Gregory Poch, Katie Kane, Jerry Haney …
[HTML][HTML] Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular …
JL Spratlin, RB Cohen, M Eadens, L Gore… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs),
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully …
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully …
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
…, JC Fitzgerald, R Aplenc, L Gore… - Blood, The Journal …, 2013 - ashpublications.org
Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with
efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with …
efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with …
Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
…, K Hu, M Zhu, JA Whitlock, L Gore - Journal of Clinical …, 2016 - ascopubs.org
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on
B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and …
B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and …
Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first …
…, E Sharon, MB Bernhardt, SA Terezakis, L Gore… - Jama, 2021 - jamanetwork.com
Importance Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL)
in children, adolescents, and young adults is associated with high rates of severe …
in children, adolescents, and young adults is associated with high rates of severe …
[HTML][HTML] Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint …
…, S Roberts, G Ison, NU Lin, L Gore… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants
and define the trial population. Excessive or overly restrictive eligibility criteria can slow …
and define the trial population. Excessive or overly restrictive eligibility criteria can slow …
Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro
G Lacaud, L Gore, M Kennedy… - Blood, The Journal …, 2002 - ashpublications.org
In this report we demonstrate a role for Runx1 (AML1)at the hemangioblast stage of hematopoietic
and endothelial development in embryonic stem (ES) cell–derived embryoid bodies (…
and endothelial development in embryonic stem (ES) cell–derived embryoid bodies (…